Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × GX-188 vaccine × Clear all
NCT03444376 2025-07-30

The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer

Genexine, Inc.

Phase 1/2 Completed
65 enrolled 16 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡